ISG15 links type I interferon pathway to cardiovascular risk in systemic lupus erythematosus
Clinical and Experimental Medicine · 10.08.2026 · 26 (1)
DOI: 10.1007/s10238-026-02275-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 10.08.2026. Verfasst von Chao Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Diagnostics, First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, NanGang, Harbin, 150001, Heilongjia…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Cytokines, Ubiquitins, Interferon Type I. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The fundamental research funds for the provincial universities in heilongjiang province.
Abstract (Originalsprache)
Patients with systemic lupus erythematosus (SLE) have significantly increased cardiovascular risk, and atherosclerosis (AS) is a major cause of long-term mortality. However, whether SLE-specific immune dysregulation drives accelerated AS remains unclear. This study explored the role of interferon-stimulated gene 15 (ISG15) in SLE-associated AS. We first characterized the disease manifestations, then identified disease characteristics at the proteomic and transcriptomic levels via multi-omics analysis of a pristane-induced SLE-ApoE-/- mouse model and integrated analysis of SLE and AS datasets. We found ISG15 was uniquely elevated across atherosclerotic plaque types and correlated with cardiovascular events, with robust interferon-alpha response activation in SLE mice. Further, ISG15 colocalized with CD68⁺ macrophages in plaques, and extended analysis showed it was highly expressed in peripheral blood monocytes of SLE patients. Clinically, ISG15⁺ monocyte proportion was significantly higher in SLE patients with AS, outperforming conventional cardiovascular risk scores and serving as an independent predictor. In conclusion, ISG15 is a critical effector linking SLE immune dysregulation to accelerated AS, and ISG15⁺ monocyte proportion is a promising biomarker for cardiovascular risk stratification in SLE patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Diagnostics, First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, NanGang, Harbin, 150001, Heilongjiang, P.R. China.
- Department of Laboratory Diagnostics, First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, NanGang, Harbin, 150001, Heilongjiang, P.R. China. gxr0451@sina.com.
Förderung
- The fundamental research funds for the provincial universities in heilongjiang province
Zitieren
APA
Wang, C., Liu, X., Fu, X., Yu, X., Li, M., & Guan, X. (2026). ISG15 links type I interferon pathway to cardiovascular risk in systemic lupus erythematosus. Clinical and Experimental Medicine, 26(1). https://doi.org/10.1007/s10238-026-02275-4
Vancouver
Wang C, Liu X, Fu X, Yu X, Li M, Guan X. ISG15 links type I interferon pathway to cardiovascular risk in systemic lupus erythematosus. Clinical and Experimental Medicine. 2026;26(1). doi:10.1007/s10238-026-02275-4
BibTeX
@article{Wang2026,
author = {Wang, Chao and Liu, Xinxin and Fu, Xingyu and Yu, Xiaochen and Li, Min and Guan, Xiuru},
title = {ISG15 links type I interferon pathway to cardiovascular risk in systemic lupus erythematosus},
journal = {Clinical and Experimental Medicine},
year = {2026},
volume = {26},
number = {1},
doi = {10.1007/s10238-026-02275-4}
}
EUVIMED